2. Signaling Pathways
  3. GPCR/G Protein
  4. Adenosine Receptor

Adenosine Receptor

P1 receptor

Adenosine Receptor

Related Products

PDF 1.74 MB

Adenosine receptors (ARs) comprise a group of G protein-coupled receptors (GPCR) which mediate the physiological actions of adenosine. To date, four AR subtypes have been cloned and identified in different tissues. These receptors have distinct localization, signal transduction pathways and different means of regulation upon exposure to agonists. A key property of some of Adenosine receptors is their ability to serve as sensors of cellular oxidative stress, which is transmitted by transcription factors, such as NF-κB, to regulate the expression of ARs. The importance of Adenosine receptors in the regulation of normal and pathological processes such as sleep, the development of cancers and in protection against hearing loss will be examined.

Adenosine Receptor Isoform Specific Products:

Adenosine Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0092R
    Inosine (Standard)
    		Agonist
    Inosine (Standard) is the analytical standard of Inosine. This product is intended for research and analytical applications. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors. In Vitro:Inosine dose-dependently stimulates cAMP production mediated through the A2AR.
    Inosine dose-dependently induces hA2AR-mediated ERK1/2 phosphorylation.
    Inosine (100 μM; 24 hours) reduces oxidative stress in MES 23.5 cells cultured with astrocytes.
    In Vivo:Inosine (10-100 mg/kg; i.p.) exhibits antinociceptive effect in mice.
    Inosine (Standard)
  • HY-17391
    Pamabrom
    		99.92%
    Pamabrom is a diuretic that acts on the opioid receptor-nitric oxide (NO) -cyclic guanosine monophosphate (cGMP) -K+ channel pathway. Pamabrom exerts peripheral antinociceptive activity by activating this pathway. The mechanism involves activating opioid receptors, promoting the release of nitric oxide, and then influencing cyclic guanosine monophosphate and K channels to produce an analgesic effect. Pamabrom is orally active and is mainly used in the research and treatment of premenstrual syndrome and primary dysmenorrhea[1].
    Pamabrom
  • HY-148088A
    M1069 free base
    		Antagonist 98.92%
    M1069 (free base) is a selective and orall active, dual A2A/A2B adenosine receptor antagonist with a selectivity of >100 fold against the A1 and A3 receptors. M1069 (free base) counteracts immune-suppressive mechanisms of adenosine, and exhibits anti-tumor activity.
    M1069 free base
  • HY-U00251
    KFM19
    		Antagonist 99.44%
    KFM19 is a potent, selective Adenosine receptor (A1-receptor) antagonist, with an IC50 of 50 nM.
    KFM19
  • HY-100032
    PD 117519
    		Agonist 99.97%
    PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models.
    PD 117519
  • HY-136233
    PSB 0777 ammonium
    		Agonist
    PSB 0777 ammonium is a potent and selective adenosine A2A receptor full agonist with Ki values of 44.4 nM, 360 nM for rat and human A2A receptors, respectively. PSB 0777 ammonium has Ki values of ≥10000 nM, 541 nM for rat and human A1 receptors, respectively. PSB 0777 ammonium shows poor brain penetrant and perorally non-absorbable effect. PSB 0777 ammonium has the potential for inflammatory bowel disease (IBS) research research.
    PSB 0777 ammonium
  • HY-10888S
    Istradefylline-13C,d3
    		Antagonist
    Istradefylline-13C,d3 is the 13C- and deuterium labeled Istradefylline. Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
    Istradefylline-<sup>13</sup>C,d<sub>3</sub>
  • HY-107046
    UK-432097
    		Agonist 98.9%
    UK-432097 is a highly potent and selective A2AAR agonist with a pKi of 8.4 for human A2AAR. UK-432097 has anti-inflammatory and anti-aggregatory properties. UK-432097 has the potential for COPD (Chronic Obstructive Pulmonary Disease) research.
    UK-432097
  • HY-103170
    LUF5834
    		Agonist 99.8%
    LUF5834 is a selective A2B adenosine receptor (A2BR) partial agonist (EC50 = 12 nM). LUF5834 is also a partial A1/A2A adenosine receptor agonist (lacking selectivity) with Ki values of 2.6 and 28 nM, respectively.
    LUF5834
  • HY-N12422
    A2AAR antagonist 2
    		Antagonist 99.40%
    3′-Methoxyfurano[4″,5″:3,4]chalcone (compound 2) is a selective A2AAR antagonist (IC50=33.5 nM) with high affinity. 3′-Methoxyfurano[4″,5″:3,4]chalcone is also a natural product obtained from the bark of Allium cepa L. 3′-Methoxyfurano[4″,5″:3,4]chalcone can promote T cell activation and can be used in cancer immunity research.
    A2AAR antagonist 2
  • HY-106007
    Trabodenoson
    		Agonist 99.97%
    Trabodenoson (INO-8875), an adenosine mimetic, is a highly selective Adenosine A1 receptor agonist. Trabodenoson (INO-8875) is used in the study for Primary Open-Angle Glaucoma.
    Trabodenoson
  • HY-120826
    A2AAR/hMAO-B-IN-1
    		Inhibitor ≥99.0%
    A2AAR/hMAO-B-IN-1 (compoudn 17) is a non-xanthine dual-target inhibitor targeting the A2A adenosine receptor (A2AAR) (IC50: 34.9 nM) andMAO-B (Ki: 39.5 nM, human). A2AAR/hMAO-B-IN-1 inhibits A2AAR-induced cAMP accumulation and exhibits competitive, reversible inhibition of MAO-B. A2AAR/hMAO-B-IN-1 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD).
    A2AAR/hMAO-B-IN-1
  • HY-131032
    KI-7
    		Agonist 99.16%
    KI-7 is an A2B adenosine receptor positive allosteric modulator. KI-7 potentiates the cAMP accumulation induced by the non-selective A2B adenosine receptor agonist NECA (EC50=445.8 nM). KI-7 also potentiates the cAMP accumulation induced by the selective A2B adenosine receptor agonist BAY 60-6583 as well as by adenosine with EC50s of 2390 nM and 2550 nM, respectively.
    KI-7
  • HY-106303
    YT 146
    		Agonist 99.72%
    YT 146 is a potent agonist of A2 adenosine receptor (A2 AR) agonist. YT 146 causes a concentreation dependent cAMP accumulation, with the EC50 of 1.5 nM. YT 146 has cardioprotective effects.
    YT 146
  • HY-165578
    Neladenoson
    		Agonist 99.95%
    Neladenoson is a potent and selective Adenosine A1 Receptor agonist. EGFR-IN-162 is promising for research of heart failure.
    Neladenoson
  • HY-103165
    PSB-0788
    		Antagonist 99.68%
    PSB-0788 is a new selective high-affinity A2B antagonist with IC50 value of 3.64 nM and Ki value of 0.393 nM, respeactively. PSB-0788 can be used for the research for chronic inflammatory lung diseases.
    PSB-0788
  • HY-10915
    LUF6096
    		Agonist 99.16%
    LUF6096, a potent allosteric enhancer of the adenosine A3 receptor, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury.
    LUF6096
  • HY-W063197
    Adenosine receptor antagonist 4
    		Antagonist 98.09%
    Adenosine receptor antagonist 4 (compound 2) is an adenosine A1 receptor antagonist with a Ki of 101 nM for human A1 receptor.
    Adenosine receptor antagonist 4
  • HY-13201
    CGS 21680
    		Agonist
    CGS 21680 is a selective adenosine A2A receptor agonist, with a Ki of 27 nM.
    CGS 21680
  • HY-10888R
    Istradefylline (Standard)
    		Antagonist
    Istradefylline (Standard) is the analytical standard of Istradefylline. This product is intended for research and analytical applications. Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
    Istradefylline (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
Adenosine Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.